Table 1.
Epidemiological parameters
| Parameter | Value | Source |
|---|---|---|
| Vaccine adherence | ||
| First primary dose | 96.7% | [15] |
| Second primary dose | 96.7% | |
| Booster dose | 96.7% | |
| Probability of IPD given carriage acquisition | ||
| Serotype 19A | 20 per 100 000 acquisitions | [19] |
| Serotype 3 | 9 per 100 000 acquisitions | |
| Serotypes 1, 5, 7F and 6A | 22 per 100 000 acquisitions | |
| PCV7-covered serotypes | 28 per 100 000 acquisitions | |
| Non-covered serotypes | 2 per 100 000 acquisitions | Calibrated |
| Duration of carriage among carriers | ||
| Serotype 19A | 12.6 weeks | [19] |
| Serotype 3 | 6.2 weeks | |
| Serotypes 1, 5, 7F and 6A | 7.4 weeks | |
| PCV7-covered serotypes | 14.2 weeks | |
| Non-covered serotypes | 6.2 weeks | Calibrated |
| Duration of immunity (PCV7 and PCV13) | ||
| First primary dose | 5.6 years | Calibrated |
| Second primary dose | 11.3 years | Calibrated |
| Booster dose | 11.3 years | Calibrated |
| PCV effectiveness against IPD (first priming dose, second priming dose, booster dose) | ||
| Serotype 19A | 53%, 75%, 74% | [17, 18] |
| Serotype 3 | 16%, 34%, 33% | |
| Serotypes 1, 5, 7F and 6A | 85%, 94%, 93% | |
| PCV7-covered serotypes | 56%, 79%, 93% | |
| Non-covered serotypes | 0%, 0%, 0% | Assumed |
| PCV effectiveness against carriage (first priming dose, second priming dose, booster dose) | ||
| Serotype 19A | 16%, 44%, 49% | [17, 18] |
| Serotype 3 | 2%, 3%, 18% | |
| Serotypes 1, 5, 7F and 6A | 53%, 54%, 69% | |
| PCV7-covered serotypes | 15%, 79%, 93% | |
| Non-covered serotypes | 0%, 0%, 0% | Assumed |
CAP, community-acquired pneumonia; IPD, invasive pneumococcal disease; N/A, not applicable; PCV, pneumococcal conjugate vaccine; PCV7, seven-valent PCV; PCV13, 13-valent PCV.